<DOC>
	<DOCNO>NCT01975077</DOCNO>
	<brief_summary>Fruquintinib novel oral small molecule compound discover developed Hutchison MediPharma selectively inhibit vascular endothelial growth factor receptor ( VEGFR ) 1 , 2 , 3 demonstrate potent inhibitory effect multiple human tumor xenografts.Based first-in-human study , 4mg QD 5mg 3wks on/1wk safety efficacy , phase Ib study evaluable safety , tolerability efficacy 2 regimen mCRC fail 2nd therapy determine recommend dose regimen phase II/III study .</brief_summary>
	<brief_title>Phase Ib Study Fruquintinib Patients With Metastatic Colorectal Carcinoma</brief_title>
	<detailed_description>This phase Ib , randomize , interventional , open-label , multicenter study provide fruquintinib subject diagnose metastatic colorectal cancer fail standard therapy therapy alternative exist . The primary endpoint study safety .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>≥ 18 ≤ 70 year age , ≥ 40Kg Histological cytological confirm colorectal cancer ECOG performance status 01 Standard regimen fail standard regimen available Adequate hepatic , renal , heart , hematologic function At least one measurable lesion ( large 10 mm diameter spiral CT scan ) Signed date informed consent . Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure Pregnant lactate woman Any factor influence usage oral administration Evidence CNS metastasis Intercurrence one following : noncontrolled hypertension , coronary artery disease , arrhythmia heart failure Abuse alcohol drug Less 4 week last clinical trial Previous treatment VEGFR inhibition Disability serious uncontrolled intercurrence infection Proteinuria ≥ 2+ ( 1.0g/24hr ) Uncontrolled hemorrhage GI Within 12 month first treatment occur artery/venous thromboembolic event , cerebral vascular accident ( include transient ischemic attack ) etc . Within 6 month first treatment occur acute myocardial infarction , acute coronary syndrome CABG Bone fracture wound cure long time Coagulation dysfunction , hemorrhagic tendency receive anticoagulant therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>patient mCRC fail 2nd therapy</keyword>
</DOC>